Natco Pharma settles dispute with Celgene in Canada

Our Bureau Hyderabad | Updated on July 10, 2020 Published on July 10, 2020

Natco Pharma (Canada) Inc., Canada, a subsidiary of Natco Pharma Ltd, has entered into a settlement agreement with Celgene (now part of Bristol-Myers Squibb) for the product Lenalidomide capsules in Canada.

“The terms of the agreement are confidential as per the agreement,” the Hyderabad-based Natco Pharma said in a release issued on Friday.

Natco’s scrip trading at ₹676.75 on the BSE on Friday, almost flat over the previous close.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on July 10, 2020
This article is closed for comments.
Please Email the Editor